Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

Leuk Lymphoma. 2014 Aug;55(8):1925-9. doi: 10.3109/10428194.2013.855309. Epub 2014 Feb 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Azacitidine / analogs & derivatives
  • Azacitidine / therapeutic use
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • DNA Methyltransferase 3A
  • Decitabine
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Mutation*
  • Prognosis
  • Treatment Outcome

Substances

  • DNMT3A protein, human
  • Decitabine
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A
  • Azacitidine